facebook
Subscribe50$/product give away!


Submit an Article to Pharmacy HQ     
Please include the author's name, title, and citations.     

FABRAZYME- agalsidase beta injection, powder, lyophilized, for solution


Patient Information

Inform patients that a Registry has been established in order to better understand the variability and progression of Fabry disease in the population as a whole and in women[seeUse in Specific Populations (8.1)], and to monitor and evaluate long-term treatment effects of Fabrazyme. The Registry will also monitor the effect of Fabrazyme on pregnant women and their offspring. Encourage patients to participate. Advise patients that their participation is voluntary and may involve long-term follow-up. For more information, visit www. registrynxt.com or call 1-800-745-4447, extension 15500.

Manufactured by:
Genzyme Corporation
50 Binney Street
Cambridge, MA 02142
U.S. License Number: 1596

Fabrazyme and Genzyme are registered trademarks of Genzyme Corporation.



Your use of this website constitutes your agreement to the terms and conditions linked below:
Terms and Conditions | Resources
2017 © Copyright PharmacyHQ.com. Questions?
Please contact: pharmacyhq.mail@gmail.com